Evotec SE (EVT)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 2.810 |
|---|---|
| 52-week range | 2.406 – 7.300 |
| Return, 1 month / 3 months | +0.4% / −18.9% |
| Return, 1 year / 3 years | −59.1% / −82.8% |
| Trend | Below its 200-day average |
| RSI (14) | 49 |
| Volatility (1 year) | 60.3% |
| Worst drawdown (1 year) | -65.8% |
| Average daily value traded | 3.00M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Evotec is a drug discovery and development company based in Germany. It works with pharmaceutical and biotechnology companies, academic institutions and foundations, offering research services and partnership arrangements that help move potential medicines from early discovery through development. Its activities span areas such as neuroscience, metabolic disease and oncology, and it combines fee-for-service research work with its own drug discovery programmes and collaborations.
Evotec SE trades under the code EVT on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Evotec SE (EVT) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 2.810 on 23 October 2026.
Its price-based Market X-Ray is 21 out of 100 (a weak price profile), ranking 624 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 59.1% and over the last three months it fell 18.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 5 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -37.0% | ||
| From 52-week high | -60.7% | ||
| Momentum | 8 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -18.9% | ||
| 6-month return | -48.0% | ||
| 12-month return, skipping the last month | -59.2% | ||
| Stability (higher is calmer) | 11 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 60.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -65.8% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 3.00M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +9.5% |
|---|---|
| 1 month | +0.4% |
| 3 months | −18.9% |
| 6 months | −48.0% |
| 1 year | −59.1% |
| 3 years | −82.8% |
| 5 years | −93.8% |
Signals
| 50-day / 200-day average | 2.983 / 4.459 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.147 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.